News and Announcements
Actinogens’ Xanamem™ to Showcase Cortisol Hypothesis
- Published June 30, 2016 10:08AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
29th Sydney 2016, ASX Announcement
Actinogen Medical (ASX:ACW) is pleased to announce the key data supporting its novel Alzheimer’s drug Xanamem™, has been selected by an independent expert panel for presentation at the world’s largest dementia research conference – the Alzheimer’s Association International conference (AAIC), in Toronto 22nd – 28th July, 2016.
The presentation entitled, “Xanamem™ a novel 188-HSD1 inhibitor with as potential to provide durable symptomatic and disease modifying benefits in Alzheimer’s disease“, will include results on Xanamem™’s succesful Phase I human trials and importantly confirm that following oral administration Xanamem™’s effectively crosses the blood-brain-barrier and gets to the brain, its primary site of action in Alzheimer’s disease.
To view the full announcement, please click on the button below.